Skip to main content

Advertisement

SpringerLink
Log in

Novel Therapeutic Approaches to Atopic Dermatitis

  • Review
  • Published:
Archivum Immunologiae et Therapiae Experimentalis Aims and scope

Abstract

Atopic dermatitis (AD) is one of the most common inflammatory skin diseases. The number of people affected by AD is relatively high and seems to be rising. Although mild and moderate forms of the disease can be well controlled by the use of emollients, topical corticosteroids, and topical calcineurin inhibitors, treatment of severe is still a huge challenge. The new hope is biologic drugs, magic bullets in allergy, targeted at different points of the complex pathomechanism of inflammation in AD. In this review, novel biologic therapies are discussed, including recombinant monoclonal antibodies directed against various interleukin pathways (such as IL-4, IL-13, TSLP, IL-31, and IL-12/23), on immunoglobulin E, molecules acting as T cells, B cells, etc. Of biological drugs, the most promising seems to be anti-IL-4/IL-13 therapy (dupilumab—the biological agent) and phosphodiesterase-4 inhibitor (crisaborole—a small molecule). A deep understanding of the AD pathomechanism provides a new perspective for tailor-made treatment of severe atopic dermatitis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  • Agusti-Mejias A, Messeguer F, García R et al (2013) Severe refractory atopic dermatitis in an adolescent patient successfully treated with ustekinumab. Ann Dermatol 25:368–370

    Article  PubMed  PubMed Central  Google Scholar 

  • Arm JP, Bottoli I, Skerjanec A et al (2014) Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects. Clin Exp Allergy 44:1371–1385

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Batista DI, Perez L, Orfali RL et al (2015) Profile of skin barrier proteins (filaggrin, claudins 1 and 4) and Th1/Th2/Th17 cytokines in adults with atopic dermatitis. J Eur Acad Dermatol Venereol 29:1091–1095

    Article  PubMed  CAS  Google Scholar 

  • Beck LA, Thaçi D, Hamilton JD et al (2014) Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med 371:130–139

    Article  PubMed  CAS  Google Scholar 

  • Bieber T, Straeter B (2015) Off-label prescriptions for atopic dermatitis in Europe. Allergy 70:6–11

    Article  PubMed  CAS  Google Scholar 

  • Boniface K, Bernard FX, Garcia M et al (2005) IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes. J Immunol 174:3695–3702

    Article  PubMed  CAS  Google Scholar 

  • Brough HA, Liu AH, Sicherer S et al (2015) Atopic dermatitis increases the effect of exposure to peanut antigen in dust on peanut sensitization and likely peanut allergy. J Allergy Clin Immunol 135:164–170

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Buka RL, Resh B, Roberts B et al (2005) Etanercept is minimally effective in 2 children with atopic dermatitis. J Am Acad Dermatol 53:358–359

    Article  PubMed  Google Scholar 

  • Chan SC, Reifsnyder D, Beavo JA et al (1993) Immunochemical characterization of the distinct monocyte cyclic AMP-phosphodiesterase from patients with atopic dermatitis. J Allergy Clin Immunol 91:1179–1188

    Article  PubMed  CAS  Google Scholar 

  • Czarnowicki T, Gonzalez J, Bonifacio KM et al (2016) Diverse activation and differentiation of multiple B-cell subsets in patients with atopic dermatitis but not in patients with psoriasis. J Allergy Clin Immunol 137(118–129):e115

    Google Scholar 

  • Eyerich K, Novak N (2013) Immunology of atopic eczema: overcoming the Th1/Th2 paradigm. Allergy 68:974–982

    Article  PubMed  CAS  Google Scholar 

  • Eyerich K, Eyerich S, Biedermann T (2015) The multi-modal immune pathogenesis of atopic eczema. Trends Immunol 36:788–801

    Article  PubMed  CAS  Google Scholar 

  • Fernández-Antón Martínez MC, Leis-Dosil V, Alfageme-Roldán F et al (2012) Omalizumab for the treatment of atopic dermatitis. Actas Dermosifiliogr 103:624–628

    Article  PubMed  Google Scholar 

  • Fernández-Antón Martínez MC, Alfageme Roldán F, Ciudad Blanco C et al (2014) Ustekinumab in the treatment of severe atopic dermatitis: a preliminary report of our experience with 4 patients. Actas Dermosifiliogr 105:312–313

    Article  PubMed  Google Scholar 

  • Gittler JK, Shemer A, Suárez-Fariñas M et al (2012) Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. J Allergy Clin Immunol 130:1344–1354

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Hanania NA, Noonan M, Corren J et al (2015) Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies. Thorax 70:748–756

    Article  PubMed  PubMed Central  Google Scholar 

  • Heil PM, Maurer D, Klein B et al (2010) Omalizumab therapy in atopic dermatitis: depletion of IgE does not improve the clinical course—a randomized, placebo-controlled and double blind pilot study. J Dtsch Dermatol Ges 8:990–998

    PubMed  Google Scholar 

  • Hotze M, Baurecht H, Rodríguez E et al (2014) Increased efficacy of omalizumab in atopic dermatitis patients with wild-type filaggrin status and higher serum levels of phosphatidylcholines. Allergy 69:132–135

    Article  PubMed  CAS  Google Scholar 

  • Howell MD, Kim BE, Gao P et al (2009) Cytokine modulation of atopic dermatitis filaggrin skin expression. J Allergy Clin Immunol 124(3 Suppl 2):R7–R12

    Article  PubMed  CAS  Google Scholar 

  • Ibler KS, Jemec GB (2015) Novel investigational therapies for atopic dermatitis. Expert Opin Investig Drugs 24:61–68

    Article  PubMed  CAS  Google Scholar 

  • Itazawa T, Adachi Y, Okabe Y et al (2003) Developmental changes in interleukin-12-producing ability by monocytes and their relevance to allergic diseases. Clin Exp Allergy 33:525–530

    Article  PubMed  CAS  Google Scholar 

  • Iyengar SR, Hoyte EG, Loza A et al (2013) Immunologic effects of omalizumab in children with severe refractory atopic dermatitis: a randomized, placebo-controlled clinical trial. Int Arch Allergy Immunol 162:89–93

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Jacobi A, Antoni C, Manger B et al (2005) Infliximab in the treatment of moderate to severe atopic dermatitis. J Am Acad Dermatol 52:522–526

    Article  PubMed  Google Scholar 

  • Kasperkiewicz M, Sufke S, Schmidt E et al (2014) IgE-specific immunoadsorption for treatment of recalcitrant atopic dermatitis. JAMA Dermatol 150:1350–1351

    Article  PubMed  Google Scholar 

  • Kim DH, Park KY, Kim BJ et al (2013) Anti-immunoglobulin E in the treatment of refractory atopic dermatitis. Clin Exp Dermatol 38:496–500

    Article  PubMed  CAS  Google Scholar 

  • Kwiek B, Novak N (2010) Immunosuppressants as treatment for atopic dermatitis. In: Pawankar R, Holgate S et al (eds) Allergy frontiers: therapy and prevention, vol V. Springer, Berlin, pp 291–310

    Google Scholar 

  • Kwiek B, Peng WM, Allam JP et al (2008) Tacrolimus and TGF-beta act synergistically on the generation of Langerhans cells. J Allergy Clin Immunol 122:126–132.e1

    Article  PubMed  CAS  Google Scholar 

  • Lacombe Barrios J, Begin P, Paradis L et al (2013) Anti-IgE therapy and severe atopic dermatitis: a pediatric perspective. J Am Acad Dermatol 69:832–834

    Article  PubMed  Google Scholar 

  • Lauffer F, Ring J (2016) Target-oriented therapy: emerging drugs for atopic dermatitis. Expert Opin Emerg Drugs 21:81–89

    Article  PubMed  CAS  Google Scholar 

  • Leitch CS, Chu R, Ray R et al (2015) Preventing atopic eczema from birth using emollients. J Allergy Clin Immunol 135:1663–1664

    Article  PubMed  Google Scholar 

  • Mangge H, Gindl S, Kenzian H et al (2003) Atopic dermatitis as a side effect of anti-tumor necrosis factor-alpha therapy. J Rheumatol 30:2506–2507

    PubMed  Google Scholar 

  • McDonald BS, Jones J, Rustin M (2016) Rituximab as a treatment for severe atopic eczema: failure to improve in three consecutive patients. Clin Exp Dermatol 41:45–47

    Article  PubMed  CAS  Google Scholar 

  • NCT00676884 (2008) A phase 2a study to investigate the effects of repeated administration of aeroderm in subjects with atopic eczema. https://clinicaltrials.gov/ct2/show/NCT00676884. Accessed 4 Jan 2017

  • NCT01614756 (2012) A two-part, phase 1, single-dose study of IL-31 mAb (anti-interleukin 31 monoclonal antibody); in healthy subjects and adults with atopic dermatitis. https://clinicaltrials.gov/ct2/show/NCT01614756. Accessed 4 Jan 2017

  • NCT01806662 (2013) Pilot study of ustekinumab for subjects with chronic atopic dermatitis. https://clinicaltrials.gov/ct2/show/NCT01806662. Accessed 4 Jan 2017

  • NCT01941537 (2013) Randomized Placebo Controlled Study to Determine Safety, Pharmacodynamics and Efficacy of ILV-094 in Atopic Dermatitis. https://clinicaltrials.gov/ct2/show/NCT01941537. Accessed 4 Jan 2017

  • NCT02087943 (2014) Efficacy and safety study of apremilast in subjects with moderate to severe atopic dermatitis. https://clinicaltrials.gov/ct2/show/NCT02087943. Accessed 24 Mar 2017

  • NCT02340234 (2015) A study of lebrikizumab in patients with persistent moderate to severe atopic dermatitis. https://clinicaltrials.gov/ct2/show/NCT02340234. Accessed 4 Jan 2017

  • NCT02407756 (2015) A study to determine the safety and tolerability of dupilumab in patients aged ≥6 to <18 years with atopic dermatitis (eczema). https://clinicaltrials.gov/ct2/show/study/NCT02407756. Accessed 4 Jan 2017

  • NCT02525094 (2015) Phase 2a study to evaluate the efficacy and safety of MEDI9929 in adults with atopic dermatitis (ALLEVIAD). https://clinicaltrials.gov/ct2/show/NCT02525094. Accessed 4 Jan 2017

  • NCT02594098 (2015) Secukinumab for Treatment of Atopic Dermatitis. https://clinicaltrials.gov/ct2/show/NCT02594098. Accessed 4 Jan 2017

  • Novak N, Kwiek B, Bieber T (2005) The mode of topical immunomodulators in the immunological network of atopic dermatitis. Clin Exp Dermatol 30:160–164

    Article  PubMed  CAS  Google Scholar 

  • Oldhoff JM, Darsow U, Werfel T et al (2005) Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis. Allergy 60:693–696

    Article  PubMed  CAS  Google Scholar 

  • Paller AS, Tom WL, Lebwohl MG et al (2016) Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. J Am Acad Dermatol 75(494–503):e6

    Google Scholar 

  • Pazyar N, Feily A, Yaghoobi R (2012) An overview of interleukin-1 receptor antagonist, anakinra, in the treatment of cutaneous diseases. Curr Clin Pharmacol 7:271–275

    Article  PubMed  CAS  Google Scholar 

  • Puya R, Alvarez-Lopez M, Velez A et al (2012) Treatment of severe refractory adult atopic dermatitis with ustekinumab. Int J Dermatol 51:115–116

    Article  PubMed  Google Scholar 

  • Raap U, Wichmann K, Bruder M et al (2008) Correlation of IL-31 serum levels with severity of atopic dermatitis. J Allergy Clin Immunol 122:421–423

    Article  PubMed  CAS  Google Scholar 

  • Ruzicka T, Hanifin JM, Furue M et al (2017) Anti-interleukin-31 receptor a antibody for atopic dermatitis. N Engl J Med 376:826–835

    Article  PubMed  CAS  Google Scholar 

  • Samorano LP, Hanifin JM, Simpson EL et al (2016) Inadequate response to ustekinumab in atopic dermatitis—a report of two patients. J Eur Acad Dermatol Venereol 30:522–523

    Article  PubMed  CAS  Google Scholar 

  • Samrao A, Berry TM, Goreshi R et al (2012) A pilot study of an oral phosphodiesterase inhibitor (apremilast) for atopic dermatitis in adults. Arch Dermatol 148:890–897

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Sanchez-Ramon S, Eguíluz-Gracia I, Rodríguez-Mazariego ME et al (2013) Sequential combined therapy with omalizumab and rituximab: a new approach to severe atopic dermatitis. J Investig Allergol Clin Immunol 23:190–196

    PubMed  CAS  Google Scholar 

  • Schafer PH, Parton A, Gandhi AK et al (2010) Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol 159:842–855

    Article  PubMed  CAS  Google Scholar 

  • Sediva A, Kayserova J, Vernerova E et al (2008) Anti-CD20 (rituximab) treatment for atopic eczema. J Allergy Clin Immunol 121:1515–1516 (author reply 1516–1517)

    Article  PubMed  Google Scholar 

  • Shirakawa I, Deichmann KA, Izuhara I et al (2000) Atopy and asthma: genetic variants of IL-4 and IL-13 signalling. Immunol Today 21:60–64

    Article  PubMed  CAS  Google Scholar 

  • Shroff A, Guttman-Yassky E (2014) Successful use of ustekinumab therapy in refractory severe atopic dermatitis. JAAD Case Rep 1:25–26

    Article  PubMed  PubMed Central  Google Scholar 

  • Simon D, Hosli S, Kostylina G et al (2008a) Anti-CD20 (rituximab) treatment improves atopic eczema. J Allergy Clin Immunol 121:122–128

    Article  PubMed  CAS  Google Scholar 

  • Simon D, Wittwer J, Kostylina G et al (2008b) Alefacept (lymphocyte function-associated molecule 3/IgG fusion protein) treatment for atopic eczema. J Allergy Clin Immunol 122:423–424

    Article  PubMed  CAS  Google Scholar 

  • Simpson EL, Bieber T, Guttman-Yassky E et al (2016) Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med 375:2335–2348

    Article  PubMed  CAS  Google Scholar 

  • Sonkoly E, Muller A, Lauerma AI et al (2006) IL-31: a new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol 117:411–417

    Article  PubMed  CAS  Google Scholar 

  • Strowd LC, Feldman SR (2017) Dupilumab for atopic dermatitis. Lancet 10(389):2265–2266

    Article  Google Scholar 

  • Tatsuno K, Fujiyama T, Yamaguchi H et al (2015) TSLP directly interacts with skin-homing Th2 cells highly expressing its receptor to enhance IL-4 production in atopic dermatitis. J Invest Dermatol 135:3017–3024

    Article  PubMed  CAS  Google Scholar 

  • Terabe M, Park JM, Berzofsky JA (2004) Role of IL-13 in regulation of anti-tumor immunity and tumor growth. Cancer Immunol Immunother 53:79–85

    Article  PubMed  CAS  Google Scholar 

  • Thaci D, Simpson EL, Beck LA et al (2016) Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet 387:40–52

    Article  PubMed  CAS  Google Scholar 

  • Toledo F, Silvestre JF, Munoz C (2012) Combined therapy with low-dose omalizumab and intravenous immunoglobulin for severe atopic dermatitis. Report of four cases. J Eur Acad Dermatol Venereol 26:1325–1327

    Article  PubMed  CAS  Google Scholar 

  • Torley D, Futamura M, Williams HC et al (2013) What’s new in atopic eczema? An analysis of systematic reviews published in 2010–11. Clin Exp Dermatol 38:449–456

    Article  PubMed  CAS  Google Scholar 

  • Wang HH, Li YC, Huang YC (2016) Efficacy of omalizumab in patients with atopic dermatitis: a systematic review and meta-analysis. J Allergy Clin Immunol 138(1719–1722):e1

    Article  Google Scholar 

  • Weidinger S, Novak N (2016) Atopic dermatitis. Lancet 387:1109–1122

    Article  PubMed  Google Scholar 

  • Wenzel S, Wilbraham D, Fuller R et al (2007) Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet 370:1422–1431

    Article  PubMed  CAS  Google Scholar 

  • Wenzel S, Ford L, Pearlman D et al (2013) Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med 368:2455–2466

    Article  PubMed  CAS  Google Scholar 

  • Wlodek C, Hewitt H, Kennedy CT (2016) Use of ustekinumab for severe refractory atopic dermatitis in a young teenager. Clin Exp Dermatol 41:625–627

    Article  PubMed  CAS  Google Scholar 

  • Wright RC (2003) Atopic dermatitis-like eruption precipitated by infliximab. J Am Acad Dermatol 49:160–161

    Article  PubMed  Google Scholar 

  • Yayli S, Irla N, Yawalkar N (2013) Adalimumab in recalcitrant severe psoriasis associated with atopic dermatitis. Case Rep Dermatol 5:332–335

    Article  PubMed  PubMed Central  Google Scholar 

  • Zane LT, Chanda S, Jarnagin K et al (2016) Crisaborole and its potential role in treating atopic dermatitis: overview of early clinical studies. Immunotherapy 8:853–866

    Article  PubMed  CAS  Google Scholar 

  • Ziegler SF, Roan F, Bell BD et al (2013) The biology of thymic stromal lymphopoietin (TSLP). Adv Pharmacol 66:129–155

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Zink A, Gensbaur A, Zirbs M et al (2016) Targeting IgE in severe atopic dermatitis with a combination of immunoadsorption and omalizumab. Acta Derm Venereol 96:72–76

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatric Respiratory Diseases and Allergy, Medical University of Warsaw, Żwirki i Wigury 63A, 02-091, Warsaw, Poland

    Katarzyna Osinka, Karolina Dumycz & Wojciech Feleszko

  2. Department of Dermatology and Immunodermatology, Medical University of Warsaw, Warsaw, Poland

    Bartłomiej Kwiek

Authors
  1. Katarzyna Osinka
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Karolina Dumycz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bartłomiej Kwiek
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wojciech Feleszko
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wojciech Feleszko.

Ethics declarations

Conflict of interest

There are no conflicts of interest to declare. All authors have approved the manuscript and agree with submission.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Osinka, K., Dumycz, K., Kwiek, B. et al. Novel Therapeutic Approaches to Atopic Dermatitis. Arch. Immunol. Ther. Exp. 66, 171–181 (2018). https://doi.org/10.1007/s00005-017-0487-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00005-017-0487-1

Keywords

Search

Navigation